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Abstract
Although evidence is accumulating that diabetes mellitus is an important risk factor for sporadic Alzheimer’s disease (AD),
the mechanisms by which defects in insulin signaling may lead to the acceleration of AD progression remain unclear. In this
study, we applied streptozotocin (STZ) to induce experimental diabetes in AD transgenic mice (5XFAD model) and
investigated how insulin deficiency affects the b-amyloidogenic processing of amyloid precursor protein (APP). Two and half
months after 5XFAD mice were treated with STZ (90 mg/kg, i.p., once daily for two consecutive days), they showed
significant reductions in brain insulin levels without changes in insulin receptor expression. Concentrations of cerebral
amyloid-b peptides (Ab40 and Ab42) were significantly increased in STZ-treated 5XFAD mice as compared with vehicle-
treated 5XFAD controls. Importantly, STZ-induced insulin deficiency upregulated levels of both b-site APP cleaving enzyme
1 (BACE1) and full-length APP in 5XFAD mouse brains, which was accompanied by dramatic elevations in the b-cleaved C-
terminal fragment (C99). Interestingly, BACE1 mRNA levels were not affected, whereas phosphorylation of the translation
initiation factor eIF2a, a mechanism proposed to mediate the post-transcriptional upregulation of BACE1, was significantly
elevated in STZ-treated 5XFAD mice. Meanwhile, levels of GGA3, an adapter protein responsible for sorting BACE1 to
lysosomal degradation, are indistinguishable between STZ- and vehicle-treated 5XFAD mice. Moreover, STZ treatments did
not affect levels of Ab-degrading enzymes such as neprilysin and insulin-degrading enzyme (IDE) in 5XFAD brains. Taken
together, our findings provide a mechanistic foundation for a link between diabetes and AD by demonstrating that insulin
deficiency may change APP processing to favor b-amyloidogenesis via the translational upregulation of BACE1 in
combination with elevations in its substrate, APP.
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Alzheimer’s disease (AD) is a devastating neurodegenerative
disorder and the most common form of dementia among the
elderly population. Although the cause of AD in sporadic forms
has not been completely determined, there is increasing consensus
that accumulation of the amyloid-b (Ab) peptide plays a central
role in triggering a cascade ultimately leading to profound
neuronal death and memory defects [1,2]. Importantly, a number
of risk factors have been identified that may shed light on the
molecular mechanisms underlying the development of sporadic
AD; in particular, recent evidence suggests a close relationship
between sporadic AD and diabetes mellitus [3–5]. Consistent with
the observation that patients with type 2 diabetes characterized by
insulin resistance are at an increased risk of getting AD, not only
reductions in insulin levels and insulin receptor expression but also
deficient downstream signaling pathways have been reported to
occur in brains of AD patients [6–9]. Furthermore, clinical data
are available on the association between AD and type 1 diabetes
resulting from hypoinsulinemia [10]. Therefore, it seems reason-
able to hypothesize that sporadic AD represents a form of diabetes
that selectively involves the brain and has the disturbed insulin
signaling pathway in common with type 1 and type 2 diabetes
mellitus [11]. This hypothesis is supported by recent findings that
analogue compounds for the incretin hormone glucagon-like
peptide-1 (GLP-1), which facilitate endogenous insulin release and
are used to treat type 2 diabetes, reduce Ab accumulation and
rescue impairments in hippocampal synaptic plasticity and spatial
learning and memory in transgenic mouse models of AD [12–14].
In a clinical setting, treatments with insulin in combination with
other antidiabetic medication are shown to lower plaque load and
benefit cognitive function in AD patients with diabetes [15,16].
Moreover, it has been demonstrated that soluble Ab oligomers
produce a loss of neuronal surface insulin receptors and directly
interfere with the insulin signaling pathway [17–20].
To further investigate an association between neuronal insulin
dysfunction and Ab accumulation in AD, streptozotocin (STZ), an
agent that selectively destroys insulin-secreting pancreatic b cells
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transgenic mice overexpressing mutant human amyloid precursor
protein (APP) [5]. Interestingly, these studies have revealed that
STZ-induced cerebral insulin deficiency in APP transgenic mice
exacerbates the development of AD-like phenotypes such as b-
amyloidosis and memory impairments [21–23]. Taken collective-
ly, different lines of experimental data suggest a link between
diabetes and AD in the pathogenesis of disease; however, the
underlying mechanism is poorly understood.
In this study, we investigated the mechanisms by which insulin
deficiency may accelerate AD progression in the 5XFAD
transgenic mouse model. 5XFAD mice co-overexpress human
APP and presenilin 1 (PS1) harboring five familial AD (FAD)
mutations [24–26]. 5XFAD mice begin to develop visible amyloid
deposition as early as 2 months of age and exhibit memory
declines on hippocampus-dependent behavioral tasks between 4–6
months concomitant with moderate Ab accumulation and
impaired synaptic physiology at Schaffer collateral-CA1 pathways
[24,25,27–29]. For our study, STZ was administered to young
5XFAD mice (1.5 months old) that have not yet developed
amyloid pathology, and we compared levels of key molecules
involved in b-amyloidosis between STZ- and vehicle-treated
subjects at 4 months of age. The molecules tested include b-site
APP cleaving enzyme 1 (BACE1), a disintegrin and metallopro-
teinase 10 (ADAM10) and PS1 responsible for the processing of
APP, full-length APP, its b- and a-cleavage products, and Ab-
degrading enzymes such as neprilysin and insulin-degrading
enzyme (IDE). We demonstrate that insulin deficiency facilitates
cerebral b-amyloidogenesis in 5XFAD mouse brains accompanied
by significant elevations in BACE1 and APP expression in the
absence of changes in levels of a-, c-secretase or Ab-degrading
enzymes. The results also suggest that translational mechanisms
through phosphorylation of eukaryotic initiation factor-2a (eIF2a)
may underlie the upregulation of BACE1 associated with insulin-
deficient diabetes.
Results
Insulin deficiency facilitates Ab accumulation in 5XFAD
mice
To examine the effects of insulin deficiency on b-amyloidosis,
5XFAD mice at 1.5 months of age were administered with STZ
(90 mg/kg, i.p.) once daily for two consecutive days after overnight
fast. Two and half months later, hemibrain samples were collected
from STZ- and saline vehicle-treated subjects. First, immunoblot
analysis of brain homogenates demonstrated that insulin levels
were significantly reduced in STZ-treated 5XFAD mice compared
with saline-treated 5XFAD controls (F(1,9)=7.98, p,0.05), while
STZ treatments did not affect insulin receptor expression (Fig. 1A,
B). Next, sandwich ELISAs were performed to compare Ab levels
in STZ- and vehicle-treated 5XFAD mice (Fig. 1C). Consistent
with previous findings [21–23], STZ-induced insulin deficiency
significantly increased cerebral levels of Ab40 (F(1,7)=7.49,
p,0.05) and Ab42 (F(1,6)=8.56, p,0.05) in 5XFAD mice.
Insulin deficiency elevates BACE1 and full-length APP in
5XFAD mice
To address the mechanisms underlying the acceleration of Ab
accumulation in STZ-induced diabetic 5XFAD mouse brains, we
first investigated changes in the b-amyloidogenic processing of
APP (Fig. 2). Immunoblot analysis demonstrated that STZ-
induced insulin deficiency elevated protein levels of the b-secretase
BACE1 in 5XFAD mice (Fig. 2A). Quantitative analysis revealed
that BACE1 expression in brains of STZ-treated 5XFAD mice
was significantly higher than that of vehicle-treated 5XFAD mice
(F(1,9)=9.49, p,0.05) (Fig. 2B). It should be noted that baseline
levels of BACE1 in vehicle-treated groups were indistinguishable
between 5XFAD and wild-type control mice at 4 months of age
(data not shown), although BACE1 expression increases with age
($9 months) in 5XFAD mouse brains [30,31], Meanwhile, STZ
treatments did not significantly affect levels of ADAM10 and PS1
associated with a- and c-secretase activities, respectively, in
5XFAD mice (Fig. 2B). Therefore, the change was specific to b-
secretase in insulin-deficient 5XFAD mice.
Figure 1. Effects of STZ-induced insulin deficiency on Ab
accumulation in 5XFAD mice. (A) Western blot analysis of hemibrain
lysates from vehicle- and STZ-treated 5XFAD mice. (B) Immunoreactive
bands for insulin and insulin receptor (IR) were quantified and
expressed as the percentage of vehicle-treated 5XFAD levels (n=4–7
mice per group). STZ treatments significantly reduced cerebral insulin
levels without affecting IR in 5XFAD mice (*p,0.05 vs. vehicle). (C)
Levels of total Ab40 and Ab42 were quantified by sandwich ELISAs of
guanidine extracts of hemibrain samples and expressed as the
percentage of vehicle-treated 5XFAD levels (n=3–5 mice per group).
Ab40 and Ab42 levels were significantly higher in brains of STZ-treated
5XFAD mice (*p,0.05 vs. vehicle). All data are presented as mean 6
SEM.
doi:10.1371/journal.pone.0032792.g001
Diabetes and BACE1 Elevation
PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e32792In addition to increases in BACE1 expression, STZ treatments
also significantly elevated levels of full-length APP, a substrate of
BACE1, in 5XFAD mice (F(1,9)=10.66, p,0.05) (Fig. 2C).
Consistent with these changes, levels of the b-cleaved C-terminal
fragment of APP (C99) were dramatically elevated (F(1,9)=21.73,
p,0.05), while levels of the secreted ectodomain of APP formed by
a-secretase cleavage (sAPPa) were significantly reduced
(F(1,9)=51.26, p,0.05) in STZ-treated 5XFAD mouse brains
(Fig. 2C). Together, these data indicate that STZ-induced insulin
deficiency alters APP processing to promote the b-amyloidogenic
pathway through the upregulation of BACE1 and APP expression.
Mechanisms by which insulin deficiency elevates BACE1
in 5XFAD mice
We next investigated whether transcriptional and/or post-
transcriptional mechanisms may underlie the BACE1 elevation
found in STZ-induced diabetic 5XFAD mice (Fig. 3). qPCR
analysis of brain homogenates revealed that BACE1 mRNA levels
were not significantly different between STZ- and vehicle-treated
5XFAD mice (Fig. 3A). Recent studies including ours demonstrate
that phosphorylation of the translation initiation factor eIF2a
(phospho-eIF2a) plays an important role in mediating the post-
transcriptional upregulationof BACE1 in sporadic AD and 5XFAD
mice at advanced stages of disease with massive amyloid pathology
[31–33].Therefore,wetestedthepossibilitythatthephospho-eIF2a
pathway may be involved in the upregulation of BACE1 in STZ-
treated5XFAD mice (Fig. 3B). In parallel with elevations inBACE1
expression, STZ-induced insulin deficiency resulted in significant
increases in phospho-eIF2a levels (F(1,9)=18.78, p,0.05) without
affecting total eIF2a levels in 5XFAD mouse brains (Fig. 3C).
Moreover, we found that STZ treatments activated PKR-
endoplasmic reticulum-related kinase (PERK: an eIF2a kinase) in
5XFAD mouse brains, as measured by a dramatic increase in a
phosphorylated form of PERK (F(1,9)=4.97, p=0.05) (Fig. 3D).
Therefore, the results suggest that translational mechanisms
through activation of the eIF2a phosphorylation pathway rather
than transcriptional mechanisms may account for the elevation of
BACE1expressioninbrainsofSTZ-induceddiabetic5XFADmice.
We further examined whether changes in the BACE1-
degrading pathway may be involved in the BACE1 elevation in
STZ-treated 5XFAD mouse brains (Fig. 3E). Recent evidence
indicates that BACE1 protein stability can be modulated by the
lysosomal degradation pathway; in particular, caspase-3-depen-
dent cleavage of Golgi-localized c-ear-containing ARF-binding
protein 3 (GGA3) is proposed to reduce BACE1 trafficking to the
lysosome and thereby cause BACE1 elevation in AD [34–37]. In
this study, STZ treatments did not induce caspase-3 activation as
assessed by increases in its 17-kDa fragments or reductions in
GGA3 levels in 5XFAD mice (Fig. 3F). Therefore, it is unlikely
that alteration of the GGA3-mediated BACE1 degradation
mechanism may underlie the upregulation of BACE1 associated
with insulin deficiency in 5XFAD mice.
Figure 2. Effects of STZ-induced insulin deficiency on APP processing in 5XFAD mice. (A) Western blot analysis of hemibrain lysates from
vehicle- and STZ-treated 5XFAD mice. Immunoreactive bands for secretases involved in the APP cleavage (B), full-length APP (fl-APP) and its
metabolites (C) were quantified and expressed as the percentage of vehicle-treated 5XFAD levels (n=4–7 mice per group). BACE1, fl-APP and C99
levels were significantly increased, while sAPPa levels were significantly reduced in STZ-treated 5XFAD mice (*p,0.05 vs. vehicle). All data are
presented as mean 6 SEM.
doi:10.1371/journal.pone.0032792.g002
Diabetes and BACE1 Elevation
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in 5XFAD mice
In addition to the facilitation of b-amyloidogenesis through BACE1
and APP elevations, it is possible that changes in the Ab metabolism
m a ya l s oc o n t r i b u t et oi n c r e a s e si nA b40 and Ab42 levels in STZ-
treated 5XFAD mice. Therefore, we examined whether STZ
treatments may affect neprilysin and/or IDE, key enzymes responsible
for the degradation and clearance of Ab peptides [38,39], in 5XAFD
mice (Fig. 4A). However, levels of neprilysin and IDE were
indistinguishable between STZ- and vehicle-treated 5XFAD mouse
brains (Fig. 4B), suggesting that increased levels of Ab accumulation in
i n s u l i n - d e f i c i e n td i a b e t i c5 X F A Dm i c ed on o tr e s u l tf r o ma l t e r a t i o n si n
these Ab-degrading enzymes.
Discussion
Consistent with epidemiological investigations showing that
diabetes is an important risk factor for sporadic AD, a growing
body of evidence indicates defective insulin signaling in AD brains
[6–9]. In this study, insulin deficiency evoked by STZ adminis-
tration in the pre-pathological stage of 5XFAD mice (1.5 months
of age) accelerated the subsequent Ab accumulation in brain,
suggesting that insulin dysfunction may not only be a consequence
of AD pathology but also play a causal role in triggering the
disease process. In other transgenic mouse models of AD, STZ-
induced cerebral insulin depletion has also been reported to
aggravate AD-like traits such as amyloid plaques, tau phosphor-
Figure 3. Mechanisms by which STZ-induced insulin deficiency elevates BACE1 levels in 5XFAD mice. (A) Real-time qPCR revealed no
difference in BACE1 mRNA levels between STZ- and vehicle-treated 5XFAD mouse brains (n=4–5 mice per group). (B, E) Western blot analysis of
hemibrain lysates from vehicle- and STZ-treated 5XFAD mice. Immunoreactive bands for phosphorylated eIF2a (p-eIF2a) and total eIF2a (C),
phosphorylated PERK (p-PERK) (D), and the 17-kDa fragment of activated caspase-3 and GGA3 (F) were quantified and expressed as the percentage of
vehicle-treated 5XFAD levels (n=4–7 mice per group). Levels of p-eIF2a, but not those of total eIF2a, were significantly elevated in STZ-treated
5XFAD mice (*p,0.05 vs. vehicle). STZ treatments also dramatically increased p-PERK levels in 5XFAD mice (p=0.05), while cleaved caspase-3 and
GGA3 levels were indistinguishable between STZ- and vehicle-treated subjects. All data are presented as mean 6 SEM.
doi:10.1371/journal.pone.0032792.g003
Diabetes and BACE1 Elevation
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Morris water maze or Barnes maze task [21–23,40]. We
confirmed and extended the previous findings by determining
the mechanisms by which STZ-induced insulin-deficient diabetes
aggravates b-amyloidosis in 5XFAD transgenic mice.
We first demonstrated that protein levels of BACE1, a key
enzyme that initiates the production of Ab peptides from their
parent molecule APP, are significantly elevated in STZ-treated
5XFAD mice. In contrast, STZ treatments did not change levels of
ADAM10 and PS1 involved in the a- and c-secretase cleavage of
APP, respectively, in 5XFAD mice. Therefore, BACE1 upregula-
tion represents a crucial mechanism linking insulin deficiency to
enhanced Ab40 and Ab42 accumulation in brain. However,
BACE1 mRNA levels were not significantly affected by STZ
treatments in 5XFAD mice, suggesting that transcriptional
mechanisms may not account for the BACE1 elevation associated
with insulin-deficient diabetes. It has been reported that increases
in phosphorylation of the translation initiation factor eIF2a may
underlie the post-transcriptional upregulation of BACE1 in brains
of sporadic AD and advanced pathological phases of 5XFAD
transgenic mice ($9 months of age) [31,33]. In the present study,
baseline levels of BACE1 in vehicle-treated 4-month-old 5XFAD
mice, which show modest Ab deposition [24], were indistinguish-
able from wild-type control levels, while STZ treatments triggered
BACE1 elevations concomitant with increased levels of phosphor-
ylated eIF2a in 5XFAD mouse brains. Therefore, the results
indicate that eIF2a phosphorylation-dependent translational
upregulation of BACE1 in response to insulin deficiency may
represent an important molecular mechanism by which diabetes
accelerates b-amyloidogenesis before significant Ab deposition
occurs during the incipient stage of sporadic AD. This idea is
supported by our recent observation that the increase in phospho-
eIF2a evoked by Sal 003, a specific inhibitor of its phosphatase,
elevates BACE1 protein levels in younger 5XFAD mice that have
not yet showed BACE1 upregulation under normal conditions
[31].
What mechanisms may underlie a link between insulin signaling
and the phosphorylation of eIF2a? It is reported that an increase
in phosphorylated eIF2a occurs in hippocampal neurons of rats
exposed to transient cerebral ischemia, while insulin administra-
tion can almost completely eliminate the phosphorylation of eIF2a
in this model [41]. Therefore, it is conceivable that insulin may
downregulate eIF2a kinase and/or upregulate eIF2a phosphatase.
In this study, we found that insulin deficiency produces robust
activation of PERK, a major eIF2a kinase, in line with elevated
levels of phospho-eIF2a in STZ-treated 5XFAD mice. This is
consistent with the observation showing that mRNA and protein
levels of PERK are significantly upregulated in STZ-injected rats
[42]. Moreover, expression of dominant-negative PERK is shown
to block energy deprivation-induced increases of both eIF2a
phosphorylation and BACE1 in HEK293 cell line cultures [33].
Although further study is required for the demonstration of a
causal link, the present data suggest that the PERK-eIF2a
phosphorylation pathway may, at least in part, play a role in
mediating the BACE1 elevation associated with deficient insulin
signaling in diabetic 5XFAD mice.
Are transcriptional or translational mechanisms responsible for
increases in protein and activity levels of BACE1 in sporadic AD
brains [43–45]? Some studies with postmortem human brains
report elevations in BACE1 mRNA levels associated with sporadic
AD [46,47], while others show no changes in mRNA despite the
increased levels of BACE1 activity and protein [48–51].
Interestingly, our previous study demonstrated that behavioral
stress elevates BACE1 protein levels concomitant with increases in
both BACE1 mRNA and a phosphorylated form of eIF2a in
5XFAD mice [52], while BACE1 expression is upregulated
without increases in mRNA levels in the diabetic 5XFAD model
in this study. Although further investigation is needed, it is
interesting to argue that differences in environmental factors,
which predominantly contribute to disease progression, may
determine whether the transcriptional and/or translational
mechanisms underlie BACE1 elevations in sporadic AD.
With regard to BACE1 stability, GGA3 has been proposed to
play a crucial role in the transport of ubiquitinated BACE1 to the
lysosomal degradation [34,36]. GGA3 is a substrate for caspase-3
cleavage; therefore, under apoptotic conditions, GGA3 inactiva-
tion by caspase-3 leads to increased BACE1 protein stability
[34,35]. Importantly, GGA3 levels are significantly decreased in
AD brains and inversely correlate with increased levels of BACE1
expression [34,37]. However, the absence of caspase-3 activation
and GGA3 reduction in our STZ-treated 5XFAD model indicates
that the mechanism of BACE1 elevation associated with diabetic
insulin deficiency is distinct from mechanisms mediated by
depletion of the BACE1-sorting protein GGA3 during apoptosis.
In addition to BACE1 elevations, levels of the substrate APP
were also upregulated in STZ-treated 5XFAD mice. Our result is
consistent with a recent report showing that expression levels of
full-length APP are increased by STZ treatments in the absence of
changes in APP mRNA levels in APP/PS1 transgenic mice [23].
Therefore, it seems likely that post-transcriptional upregulation of
both BACE1 and its substrate APP may work cooperatively,
leading to significant acceleration of b-amyloidogenesis in brains
of insulin-deficient diabetic AD mice.
Figure 4. Effects of STZ-induced insulin deficiency on neprily-
sin and IDE levels in 5XFAD mice. (A) Western blot analysis of
hemibrain lysates from vehicle- and STZ-treated 5XFAD mice. (B)
Immunoreactive bands for neprilysin and IDE were quantified and
expressed as the percentage of vehicle-treated 5XFAD levels (n=4–7
mice per group). There was no difference in neprilysin or IDE levels
between STZ- and vehicle-treated 5XFAD mice. All data are presented
as mean 6 SEM.
doi:10.1371/journal.pone.0032792.g004
Diabetes and BACE1 Elevation
PLoS ONE | www.plosone.org 5 March 2012 | Volume 7 | Issue 3 | e32792In contrast, STZ treatments did not affect levels of the Ab-
degrading enzymes such as neprilysin and IDE in 5XFAD mouse
brains. Our present results as well as others [23] indicate that the
facilitation of Ab production, which is accompanied by increases
in the intermittent b-cleaved C-terminal fragment C99 resulting
from elevated BACE1 and APP expression, may account for the
exacerbation of Ab accumulation in brains of STZ-induced
diabetic AD transgenic mice. These findings are in contrast with a
report showing that STZ-induced insulin deficiency caused
reductions in IDE without affecting C99 levels in APP mice,
suggesting that diabetes-associated exaggeration of b-amyloidosis
may be a result of reduced Ab degradation rather than increased
Ab generation [21]. This discrepancy may arise from differences
in transgenic AD mouse models used for the experiments and the
age tested or the extent to which STZ treatments reduce cerebral
insulin levels. Further study will be required to address the relative
contribution of increased generation and/or reduced degradation
of Ab to the enhanced b-amyloidosis in diabetic AD mice, with
special focus on the relationship to alterations in insulin signaling
pathways.
In conclusion, the results presented here demonstrate that STZ-
induced insulin-deficient diabetes exacerbates Ab accumulation by
elevating expression levels of the b-secretase enzyme BACE1 and
its substrate APP in the 5XFAD mouse model of AD. BACE1
elevations in diabetic 5XFAD mouse brains seem to be associated
with translational upregulation through the PERK-eIF2a phos-
phorylation pathway rather than transcriptional mechanisms or
changes in the GGA3-dependent lysosomal degradation. Our data
support the hypothesis that deficient insulin signaling may
represent a critical contributing factor in the acceleration of b-
amyloidogenesis during the progression of sporadic AD and thus
may be an important therapeutic target in AD treatments.
Materials and Methods
Animals
We used 5XFAD transgenic mice (Tg6799 line) that co-
overexpress FAD mutant forms of human APP (the Swedish
mutation: K670N, M671L; the Florida mutation: I716V; the
London mutation: V717I) and PS1 (M146L; L286V) transgenes
under transcriptional control of the neuron-specific mouse Thy-1
promoter [24–26]. 5XFAD lines (B6/SJL genetic background)
were maintained by crossing hemizygous transgenic mice with B6/
SJL F1 breeders (Taconic, Hudson, NY, USA). 5XFAD transgenic
mice used were hemizygotes with respect to the transgene and
non-transgenic wild-type littermate mice served as controls.
Genotyping was performed by PCR analysis of tail DNA, as
described [24]. Procedures were conducted in accordance with the
National Institutes of Health Guide for the Care and Use of
Laboratory Animals and approved by the Nathan Kline Institute
Animal Care and Use Committee (Assignment number: AP2008-
268).
Induction of insulin-deficient diabetes
5XFAD and wild-type control mice at 1.5 months of age were
fasted overnight and received an intraperitoneal injection of
streptozotocin (STZ, Sigma-Aldrich, St Louis, MO, USA) at
90 mg/kg or saline vehicle once daily for two consecutive days.
The mice were sacrificed at 4 months of age and brain samples
were collected for analysis.
Immunoblot analysis
Hemibrain samples were taken from the mice under deep
isoflurane anesthesia and were snap-frozen for biochemical assays.
For western blot analysis, each sample was homogenized in
5 volumes of modified RIPA buffer containing 150 mM NaCl,
50 mM Tris HCl (pH 8.0), 1 mM EDTA, 1% IGEPAL, 0.5%
sodium deoxycholate, 0.1% SDS and protease/phosphatase
inhibitor cocktail (Calbiochem, La Jolla, CA, USA), and
centrifuged at 10,000 g for 10 min to remove any insoluble
material. Protein concentrations were determined by a BCA
protein assay kit (Pierce, Rockford, IL, USA), and 20–50 mgo f
protein was run on 4–12% NuPAGE gels (Invitrogen, Carlsbad,
CA, USA) and transferred to nitrocellulose membranes. After
blocking, membranes were probed with anti-insulin (1:500, sc-
9168, Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-
insulin receptor (1:2,000, MABS65, Millipore, Billerica, MA,
USA), anti-BACE1 (1:1,000, MAB5308, Millipore), anti-AD-
AM10 (1:2,500, 422751, Calbiochem), anti-PS1 (1:1,000,
529591, Calbiochem), an antibody that recognizes C-terminal
epitope in APP (1:1,000, C1/6.1, kindly provided by Dr. Paul
Mathews, Nathan Kline Institute) to detect full-length APP/C-
terminal fragments, anti-sAPPa (1:500, 11088, Immuno-Biological
Laboratories, Minneapolis, MN, USA), anti-phospho-eIF2a
(Ser51) (1:1,000, #3398, Cell Signaling Technology, Danvers,
MA, USA), anti-eIF2a (1:2,000, #9722, Cell Signaling Technol-
ogy), anti-phospho-PERK (Ser713) (1:500, #649401, BioLegend,
San Diego, CA, USA), anti-cleaved caspase-3 (Asp175) (1:1,000,
#9661, Cell Signaling Technology), anti-GGA3 (1:1,500, #4167,
Cell Signaling Technology), anti-neprilysin 1:2,000, ab951,
Abcam, Cambridge, MA, USA), anti-IDE (1:2,000, PC730,
Millipore) or anti-b-actin (1:15,000, AC-15, Sigma-Aldrich). They
were then incubated with horseradish peroxidase-conjugated
secondary IgG. Immunoblot signals were visualized by an ECL
chemiluminescence substrate reagent kit (Pierce) and were
quantified by densitometric scanning and image analysis using
Quantity One software (Bio-Rad Laboratories, Hercules, CA,
USA).
ELISAs of Ab40 and Ab42
Sandwich Ab ELISAs were performed as described previously
[30,31,53]. Briefly, each hemibrain sample was extracted in 8X
cold 5 M guanidine HCl plus 50 mM Tris HCl (pH 8.0) buffer,
and centrifuged at 20,000 g for 1 h at 4uC to remove insoluble
material. Final guanidine HCl concentrations were below 0.1 M.
Protein concentrations were determined by a BCA kit (Pierce). To
quantitate total levels of cerebral Ab40 and Ab42, supernatant
fractions were analyzed by a well-established human Ab40 and
Ab42 ELISA kits (KHB3481 and KHB3441, Invitrogen),
respectively, according to the protocol of the manufacturer.
Optical densities at 450 nm of each well were read on a VersaMax
tunable microplate reader (Molecular Devices, Sunnyvale, CA,
USA), and sample Ab40 and Ab42 concentrations were
determined by comparison with the respective standard curves.
Ab40 and Ab42 concentration values were normalized to total
brain protein concentrations and expressed as the percentage of
vehicle controls.
Real-time qPCR
qPCR was performed in triplicate on frozen hemibrain samples
as described previously [52,54,55]. TaqMan qPCR primers were
utilized for mouse BACE1 mRNA (Mm00478671_m1, Applied
Biosystems, Foster City, CA, USA) and the housekeeping gene
glyceraldehyde-3-phosphate dehydrogenase (GAPDH, Mm9999
9915_g1, Applied Biosystems). Samples were assayed on a real-
time qPCR cycler (7900HT, Applied Biosystems) in 96-well optical
plates covered with optical adhesive film. Standard curves and
cycle threshold were generated using standards obtained from total
Diabetes and BACE1 Elevation
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was employed to determine relative gene level differences between
STZ- and vehicle-treated 5XFAD mice with GAPDH qPCR
products used as a control, and expression levels were presented as
the percentage of vehicle controls. Negative controls consisted of
the reaction mixture without input RNA.
Statistical analysis
Significant differences between groups were determined by a
one-way ANOVA and post-hoc Fisher’s PLSD tests were performed
when appropriate. Data were presented as mean 6 SEM and the
level of significance was set for p value less than 0.05.
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